Kingsview Wealth Management, LLC Argenx Se Transaction History

Kingsview Wealth Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$342.17 - $402.31 $4,448 - $5,230	-13 Reduced 2.25%	564 $213,000
Q3 2022 Nov 14, 2022	SELL	$343.2 - $395.75 $3,432 - $3,957	-10 Reduced 1.7%	577 $204,000
Q2 2022 Aug 16, 2022	SELL	$269.58 - $378.88 $199,758 - $280,750	-741 Reduced 55.8%	587 $222,000
Q1 2022 Feb 08, 2024	BUY	$254.45 - $351.06 $373,532 - $515,356	1,468 New	1,468 $462,000
Q4 2021 Feb 17, 2022	BUY	$272.01 - $353.03 $361,229 - $468,823	1,328 New	1,328 $465,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $31.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Kingsview Wealth Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Kingsview Wealth Management, LLC with notifications on news.